1	SARS-CoV-2 dynamics in New York City during March 2020–August 2023
2	Wan Yang, ^{1*} Hilary Parton, ² Wenhui Li, ² Elizabeth A. Watts, ^{2,3} Ellen Lee, ² Haokun Yuan ¹
3	¹ Department of Epidemiology, Columbia University, New York, NY, USA; ² New York City
4	Department of Health and Mental Hygiene, Queens, NY, USA; ³ Centers for Disease Control and
5	Prevention, Atlanta, GA, USA
6	*Correspondence to: wy2202@cumc.columbia.edu (WY)
7	
8	Abstract
9	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widespread since
10	2020 and will likely continue to cause substantial recurring epidemics. However, understanding
11	the underlying infection burden (i.e., including undetected asymptomatic/mild infections) and
12	dynamics, particularly since late 2021 when the Omicron variant emerged, is challenging due to
13	the potential for asymptomatic and repeat SARS-CoV-2 infection, changes in testing practices,
14	and changes in disease reporting. Here, we leverage extensive surveillance data available in
15	New York City (NYC) and a comprehensive model-inference system to reconstruct SARS-CoV-2
16	dynamics therein from the pandemic onset in March 2020 to August 2023, and further validate
17	the estimates using independent wastewater surveillance data. The validated model-inference
18	estimates indicate a very high infection burden totaling twice the population size (>5 times
19	documented case count) but decreasing infection-fatality risk (a >10-fold reduction) during the
20	first 3.5 years. The detailed estimates also reveal highly complex variant dynamics and immune
21	landscape, changing virus transmissibility, and higher infection risk during winter in NYC over
22	this time period. These transmission dynamics and drivers, albeit based on data in NYC, may be
23	relevant to other populations and inform future planning to help mitigate the public health
24	burden of SARS-CoV-2.
25	
26	INTRODUCTION
27	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019.
28	Within months, it quickly spread worldwide, prompting the World Health Organization (WHO)
29	to declare coronavirus disease 2019 (COVID-19) a global public health emergency on January
30	30, 2020, a designation lasting for 3+ years through May 5, 2023 (1). Populations worldwide
31	have experienced multiple COVID-19 pandemic waves, and will likely continue to endure
32	recurring epidemics, even after the declared ending of the pandemic phase. Given the disease's
33	historical importance, high potential to cause future epidemics, and long-term health impacts
34	(e.g., long-COVID (2)), it is important to better understand its transmission dynamics, infection
35	burden, and severity over time.
36	
37	Many studies have reported SARS-CoV-2 transmission dynamics during the initial and
38	subsequent pandemic waves (3). However, transmission dynamics after the Omicron BA.1 wave

- 39 remain less characterized. Many Omicron subvariants have emerged after BA.1, causing
- 40 outbreaks with varying magnitude and quickly supplanting one another (4). While surveillance
- 41 systems (e.g., registries of laboratory-reported cases and death certificates) can provide
- 42 invaluable information, potential biases (e.g., due to differential test-seeking behaviors) could
- 43 limit the understanding of epidemic dynamics (5-7). For example, underlying SARS-CoV-2
- 44 infection rates were not completely captured by surveillance based on clinical testing due to
- 45 high rates of asymptomatic and mild infection (8, 9) and use of at-home testing, the results of
- 46 which are not reported to health departments (10), nor were they captured by serologic
- 47 surveys due to high rates of reinfection. Due to these limitations, to what extent populations
- 48 are (re)infected by each subvariant and what drives the Omicron-subvariant waves e.g.,
- 49 increased transmissibility and/or immune evasion remain unclear.
- 50
- 51 In this study, we leverage extensive surveillance data available in New York City (NYC) and a
- 52 comprehensive model-inference system to reconstruct the underlying SARS-CoV-2 transmission
- 53 dynamics therein during March 2020 August 2023. NYC is a densely populated, large, urban
- 54 center with 8+ million people that became one of the first pandemic epicenters in March 2020.
- 55 We have previously reported model-inference estimates for the first two pandemic waves (11-
- 56 13). Here, we fit a more detailed model to age- and neighborhood-specific data of COVID-19
- 57 cases, emergency department (ED) visits, and deaths, and validate model-inference estimates
- 58 using independent SARS-CoV-2 wastewater viral load data, i.e., measurements of population-
- 59 level SARS-CoV-2 fecal shedding that are less subject to testing biases. The validated model-
- 60 inference estimates allow quantification of weekly infection rates by each (sub)variant and key
- 61 epidemiologic features including the underlying population susceptibility, variant-specific
- 62 transmissibility, and infection-fatality risk (IFR) over time since the pandemic onset. Overall, we
- 63 estimate a very high infection burden totaling twice the population size (>5 times the case
- 64 count) but decreasing IFRs (a >10-fold reduction across all age groups), and highlight several
- 65 key factors driving transmission dynamics, during the initial 3.5 years of SARS-CoV-2 circulation.
- 66
- 67 RESULTS

68 The model-inference system reconstructed underlying SARS-CoV-2 infection dynamics that

- 69 are consistent with independent SARS-CoV-2 wastewater surveillance data.
- 70 The model-inference system is able to recreate the epidemic curves of weekly cases, ED visits,
- and deaths, combining all ages (Fig 1A) and for individual age groups (Fig S1). Given the large
- 12 uncertainty due to changes in clinical testing and reporting requirements, we further validate
- 73 the estimates using independent SARS-CoV-2 wastewater surveillance data not used for model
- 74 inference. As shown in Fig 1B, the estimated number of infectious people per 100,000
- population per week closely tracked the measured SARS-CoV-2 load in wastewater. This close
- agreement is evident for all three major periods, i.e., the 2nd wave mostly due to the ancestral

and lota variants during Fall 2020/Winter 2021 (Fig 1B, 1st panel; Pearson correlation coefficient

- r = 0.91, 95% confidence interval [CI]: 0.84-0.95), the Delta wave during Summer/Fall 2021 (Fig
- ⁷⁹ 1B, 2nd panel; *r* = 0.64, 95% CI: 0.29-0.84), and the Omicron period since late November 2021
- 80 (Fig 1B, 3^{rd} panel and inset for recent months; r = 0.89, 95% CI: 0.84-0.93). These results
- 81 indicate the model-inference system adequately accounted for changing infection-detection
- 82 rates over time, and accurately reconstructed the underlying SARS-CoV-2 infection rates and
- 83 transmission dynamics during the study period.
- 84

85 Overview of the COVID-19 pandemic/epidemic dynamics through August 2023

- 86 During the study period (the week starting March 1, 2020, to the week starting August 27,
- 87 2023), 3.2 million confirmed and probable cases were reported to the NYC Department of
- 88 Health and Mental Hygiene (NYC Health Department) (or 38.2% of the size of the city's
- 89 population; Table 1). However, estimated infections totaled 17.4 million [95% credible interval
- 90 (Crl): 14.2-21.5], more than five times the documented case count. During the pre-Omicron
- 91 period (March 2020 November 2021), the model-inference system estimated cumulative
- 92 infections totaling 53.7% (95% CrI: 43.7-64.6%) of the size of the city's population; these
- 93 estimates include all infections, and do not distinguish between initial and subsequent
- 94 infections for the same individual. Most of these infections were caused by the ancestral and
- 95 Iota variants during the 1st and 2nd waves (estimated 38.0% of the size of the city's population,
- 96 95% CrI: 19.7-75.4%), followed by Delta (8.4%, 95% CrI: 4.9-21.3%) and Alpha (2.9%, 95% CrI:
- 97 1.5-5.6%).
- 98

During the Omicron period (November 2021 – August 2023), (re)infections by the Omicron
subvariants alone tripled, totaling 12.9 million (95% CrI: 10.5-16.1), or 153.3% (95% CrI: 124.8-

- 101 192.0%) of the size of the city's population. The BA.1 wave was the largest Omicron-subvariant
- 102 wave thus far, infecting around 40% of the size of the city's population, or 3.5 million people
- 103 (95% Crl: 2.2-5.6), within roughly two months (Table 1 and Fig 2A). After BA.1 subsided,
- 104 multiple Omicron subvariants circulated in NYC. By the end of August 2023, at least 14 Omicron
- 105 subvariants including BA.1 had an estimated cumulative infection rate surpassing 1% of the
- 106 city's population size (vs. only four such variants prior to Omicron; Table 1). Multiple smaller
- 107 Omicron-subvariant waves occurred, often with several subvariants cocirculating (Fig 2A). Most
- 108 notably, the BA.2/BA.2.12.1 wave occurred during Spring/Summer 2022, the BA.5 wave during
- 109 Summer/Fall 2022, and the XBB.1.5 wave during Winter 2023, each infecting around 20% of the
- 110 size of the city's population (Table 1 and Fig 2A).
- 111

112 Key factors driving SARS-CoV-2 transmission dynamics.

- 113 SARS-CoV-2 transmission dynamics have been driven by multiple factors, including use of
- 114 nonpharmaceutical interventions (NPIs), population immunity (due to prior infection and/or

- 115 vaccination), new variants, and seasonal risk of infection (11-13), all of which were accounted
- 116 by the model-inference system (see Methods). Since NPIs have become less prevalent during
- more recent waves (e.g., mask mandate in NYC schools was lifted in March 2022 (14)), here we
- 118 focus on reporting the impact of the other aforementioned factors.
- 119

120 First, population susceptibility varies following surges in infections, vaccinations, and

- 121 circulations of immune evasive variants (Fig 2B), and in turn determines the epidemic
- 122 trajectory. Before the Delta wave, mixed immunity from both prior infections and vaccinations
- 123 collectively lowered population susceptibility such that the sums (stacked bars, from top to
- 124 bottom, in Fig 2B; see details in Methods) closely tracked the complement of estimated
- 125 susceptibility (i.e., the estimated composite population immunity against infection; see blue
- 126 line and shaded area in Fig 2B). The Delta variant partially evaded both infection- and vaccine-
- 127 induced immunity (15, 16) such that the estimated susceptibility substantially increased during
- 128 the Delta wave; the estimated population immunity was lower than the sum of prior infections
- 129 and vaccinations (note this sum would roughly reflect the maximum of expected population
- 130 immunity, should there be no immune evasion; see the stacked bars dipping below the blue
- 131 line in Fig 2B). Nonetheless, strong mixed immunity at the time (>50%; see stacked bars and
- 132 blue lines in Fig 2B) likely helped to temper the intensity of the Delta wave in Summer 2021.
- 133

134 Omicron BA.1 was highly immune evasive against all pre-existing variants (17-19). After

- 135 adjusting for the lower vaccine effectiveness and weaker immunity from pre-Omicron
- 136 infections (see Methods), the combined mixed immunity (stacked bars) closely matched the
- 137 complement of estimated susceptibility (blue line) during the BA.1 wave (Fig 2B). It is evident
- 138 from Fig 2B that rapid accumulation of BA.1 infection (pink bars) along with fast uptake of the
- 139 3rd vaccine dose (open bars) at the time substantially increased population immunity, which
- 140 likely accelerated the decline of BA.1. The large BA.1-infection-induced immunity also appeared
- 141 to curb immediate surge of subsequent Omicron subvariants particularly, BA.2/BA.2.12.1 and
- 142 BA.5, even though these subvariants were able to partially evade that prior immunity (20, 21)
- 143 (Fig 2B, see the stacked bars dipping below the blue line during Summer 2022). However, in Fall
- 144 2022/Winter 2023, infection-induced immunity appeared to come from a large number of post-
- BA.1 subvariants, accumulated through their continued spread (see increasing number of
- 146 colors, each representing one subvariant, during the last part of the study period in Fig 2 A and
- 147 В).
- 148
- 149 Second, virus transmissibility (R_{TX}) can increase, helping newer variants to outcompete pre-
- 150 existing ones. Here, to capture virus-specific transmissibility (17, 22), we separated the effects
- 151 of changing population susceptibility, NPIs, and seasonal risk of infection. Unlike the effective
- 152 reproduction number *R*_t (i.e., the average number of secondary infections (23)), which can

- 153 fluctuate due to the aforementioned effects, changes in *R*_{TX} closely followed the surge of major
- variants (see large drops in *R*_t around the pandemic onset due to NPIs in Fig S2A vs. the relative
- 155 stable R_{TX} in Fig 2C). That is, here R_{TX} is akin to the basic reproduction number R_0 (i.e., the
- average number of secondary infections *in a naïve population* (23)) that measures the inherent
- 157 transmissibility of a virus, and can be tracked over time for, e.g., new variants (vs. *R*₀ being
- 158 estimated only at the pandemic onset when the entire population is susceptible; see Methods
- 159 and refs (17, 22)).
- 160
- 161 In the above context, we estimate that virus transmissibility (*R*_{TX}) has increased by nearly 3-fold
- 162 in three years, but has appeared to level off since the latter half of 2022 (Fig 2C). Consistent
- 163 with previous estimates (13, 24), lota and Alpha increased virus transmissibility, allowing them
- 164 to outcompete the ancestral variant during the 2^{nd} wave. In NYC, R_{TX} increased by ~20% during
- 165 the 2nd wave largely due to the mixed circulation of lota and Alpha (Table 2). The Delta variant
- 166 further increased virus transmissibility by another ~30% (or ~60% compared to the ancestral
- variant; Table 2), which, along with its immune evasive ability, allowed it to spread during
- 168 Summer and Fall 2021 despite the relatively high population immunity at the time (Fig 2B). The
- 169 Omicron BA.1 subvariant further increased virus transmissibility. In NYC, average R_{TX} during the
- BA.1 wave was 2.3 times the 1st (ancestral variant) wave and further increased by ~20% post-
- BA.1. Importantly, R_{TX} remained around the same level through August 2023 (Table 2 and Fig
- 172 2C), suggesting immune evasion and waning immunity (Fig S2D) have been stronger drivers of
- 173 the subvariant turnover since Summer 2022.
- 174
- 175 Third, seasonal conditions such as humidity and temperature may modulate the transmission of
- 176 respiratory viruses including SARS-CoV-2 (25-28); in particular, low humidity and low
- 177 temperature conditions commonly seen during the winter are conducive for SARS-CoV-2
- 178 survival (25). In addition, indoor crowding with reduced ventilation may also facilitate
- 179 transmission (29). While infection rates could surge during summer months when new variants
- 180 emerge, higher infection rates have occurred during winter months, peaking in December or
- 181 January in NYC during the 3.5-year study period (Fig 3A). This pattern is further evident from Fig
- 182 3B, where the scaled infection rates during winter months were often more than twice as high
- 183 as the summer months. This timing, despite multiple concurrent drivers including new variant
- 184 emergence, highlights higher SARS-CoV-2 infection risk during the winter months in NYC during
- 185 this study period.
- 186

187 Changes in infection-detection rate

- 188 The infection-detection rate (i.e., case ascertainment rate) represents the proportion of
- 189 infections detected as cases, and is crucial for accurate estimation of specific outcomes (e.g.,
- 190 infection rates and infection-fatality risk) to inform public health response (30). Estimating the

- 191 infection-detection rate of SARS-CoV-2 has been challenging due to multiple factors (e.g.,
- 192 undetected asymptomatic/mild infections) (5, 6, 30). Here we resolved these challenges by
- 193 comprehensive model inference (see Methods) and validated estimated infection-detection
- 194 rates in NYC using independent wastewater surveillance data (Fig 1). In NYC, estimated
- 195 infection-detection rates were very low at the onset of the 1st pandemic wave and the Omicron
- 196 BA.1 wave only 2.1% (95% Crl: 0.2-4.5%) and 3.0% (95% Crl: 1.1-5.4%) of infections were
- 197 detected as cases, respectively (Fig 3C). Estimated infection-detection rate increased
- 198 substantially after the initial weeks of the pandemic but fluctuated over time (Fig 3C); the
- highest rates were estimated during the week of January 3, 2021 (42.7%, 95% Crl: 27.9-56.2%)
- 200 before the Omicron variant emerged, and during the week of December 12, 2021 following the
- 201 emergence of Omicron BA.1 (45.7%, 95% CrI: 28.4-67.2%). However, estimated infection-
- 202 detection rate decreased steadily over time after Spring 2022 and was just ~5% since Summer
- 203 2023 (Fig 3C), which is comparable to the initial weeks of the pandemic.
- 204

205 Changes in infection-fatality risk (IFR)

- 206 IFR is a key indicator of COVID-19 severity. As reported previously, IFR of SARS-CoV-2 increased
- 207 log-linearly with age (*31, 32*), particularly before mass-vaccination. Thus, we estimated IFR by
- age group (see Fig 4, Table 2 and Table S1). Consistent with previous reports (*12, 13, 33, 34*),
- 209 estimated IFR in NYC was highest during the 1st wave (March May 2020). By the 2nd wave
- 210 (roughly October 2020 May 2021), IFR had declined by more than half for most age groups,
- even though it increased transiently due to circulation of variants such as lota and Alpha (Fig 4
- D and E for those older than 65 years; and Table S2). During the latter half of 2021, IFR
- 213 continued to decline, which likely was influenced by greater population immunity (Fig 2B).
- 214 Another substantial decline in IFR occurred following the circulation of Omicron BA.1, which
- 215 was milder than pre-existing variants as reported previously (35). In NYC, estimated IFR during
- the Omicron BA.1 wave (December 2021- February 2022) declined by around half compared to
- 217 the Delta wave (July November 2021), for most age groups (Fig 4 and Table S1). After the
- 218 Omicron BA.1 wave, overall IFR continued to decline, mostly driven by the lowering IFR among
- those aged 75 or older (Fig 4 E and F; Table 2 and Table S1). Starting the week of April 23, 2023,
- 220 COVID-19 deaths were classified in NYC per a revised definition (see Methods). To examine the
- 221 potential impact due to this change, we have also computed IFR including only weeks before
- the April 23, 2023 revision. The stratified IFR estimates were similar to those through the week
- 223 of August 27, 2023 (Table S1).
- 224
- 225 DISCUSSION
- 226 Using comprehensive model inference and data, we have reconstructed the transmission
- dynamics of SARS-CoV-2 in NYC during March 2020 August 2023. The detailed model-
- 228 inference estimates, further validated using independent SARS-CoV-2 wastewater surveillance

data (Fig 1), can be used to inform future planning in the city (e.g., to gauge future SARS-CoV-2

230 infection burden and related health care needs). In addition, these estimates help to reveal the

- highly complex infection dynamics of SARS-CoV-2 and illustrate the key drivers in its continued
- spread, which may be shared by other populations. Below we focus on highlighting the general
- 233 SARS-CoV-2 dynamics and key driving mechanisms.
- 234

235 By the end of August 2023, the estimated infection rate totaled twice the population size, 236 indicating the majority of NYC residents may have had at least 2 (re)infections during the first 237 3.5 years. In addition, 81% of the population received the primary COVID-19 vaccine series, 40% 238 have had an additional monovalent dose, and 23% have had either two additional monovalent 239 doses or a bivalent vaccine (NYC vaccination data; as of 8/31/2023). In combination, these 240 estimates and data suggest a high mixed population immunity. The high mixed population 241 immunity would likely help mitigate the severity of future epidemics. Estimated IFR dropped by 242 more than 10-fold for most age groups by August 2023, potentially attributable to multiple 243 factors, including accumulated mixed immunity, access to improved treatment, and circulation 244 of the milder Omicron subvariants. The potential long-term population health impact of this 245 high infection rate is uncertain given the possibility of post-acute sequelae of SARS-CoV-2

246 infection (i.e., long-COVID (2, 36)).

247

248 As noted previously (3), the ability of SARS-CoV-2 to sustain continued spread in an already 249 highly infected/vaccinated population has largely come from new variants, which can evade 250 prior immunity and/or increase transmissibility. However, the dynamics and relative 251 importance of these drivers have changed over time. Here, our estimates for NYC help to 252 inform the interaction of these drivers during the first 3.5 years. When the underlying infection 253 rate was relatively low (e.g., the first two waves), our estimates showed increased virus 254 transmissibility predominantly drove SARS-CoV-2 variant dynamics (e.g., Alpha outcompeting 255 pre-existing variants). As infections and immunity accumulated, we found stronger immune 256 evasion allowed new variants to outcompete pre-existing and co-circulating subvariants, 257 though transmissibility could also increase (Delta and BA.1 are both exemplars). By mid-2022, 258 virus transmissibility appeared to stabilize after a nearly 3-fold increase (Fig 2C). Meanwhile, 259 immune evasion continued but appeared to occur across multiple subvariants, each with a 260 smaller subset of mutations, which may have allowed them to co-circulate and traverse pockets 261 of resusceptible subpopulations (Fig 2B, see small changes in susceptibility after the Omicron 262 BA.1 wave, despite substantial infections by 10+ Omicron subvariants). Whether this is a typical 263 pathway of viral evolution to endemicity or whether another major Omicron BA.1-like new 264 variant would emerge due to the nearly saturated immune landscape remains unknown. 265

266 The decrease in COVID-19 testing and data collection since early 2022 has raised concerns of 267 timely situational awareness including new variant detection (37-39). Since late 2022/early 268 2023, the United States national surveillance strategy (40, 41) has further shifted to mainly 269 monitoring infection trends and severity (e.g., hospitalizations and mortality), along with 270 genomic surveillance and wastewater surveillance. Here, we estimated very low initial 271 infection-detection rates – roughly, only 1 in 50 infections were detected – at the onset of the 272 first pandemic wave and Omicron BA.1 wave in NYC. In addition, we found that population 273 mobility (an indicator of community mitigation via social distancing (11, 42-44)) was inversely 274 correlated with infection-detection rates during the initial weeks - that is, the lack of 275 community mitigation coincided with low infection-detection rates at the time (see preliminary 276 analysis in Table S2). The low infection-detection rates may have facilitated unchecked silent 277 spread of SARS-CoV-2 during those initial weeks, as it likely did in other places (45). While the 278 infection-detection rate increased by more than 10-fold during the pandemic, it has again 279 declined to a very low level (Fig 3C). A fuller appreciation of under-detection in the design and 280 implementation of surveillance systems is thus needed, as are innovative approaches to 281 increase detection and awareness (e.g., wastewater surveillance with timely data sharing (46)). 282

283 Lastly, we note several study limitations. First, we did not account for population migration, 284 which could lead to overestimation of the increase in susceptibility. In particular, the increase in 285 population susceptibility after the Omicron BA.1 wave could be in part due to incoming 286 population with a higher susceptibility than local residents (as NYC likely had a larger Omicron 287 BA.1 wave and higher vaccination coverage than elsewhere), rather than entirely due to 288 immune evasion of subsequent Omicron subvariants. Second, due to the discontinuation of 289 SafeGraph mobility data (47), for weeks in 2023, we used mobility trends constructed based on 290 historical data during the pandemic years 2020-2022 (vs. real-time mobility data for weeks 291 before 2023; see Methods) to account for the impact of NPIs. However, we do not expect this 292 to substantially affect the model-inference estimates, as the historical mobility trend was 293 consistent with real-time subway ridership data (Fig S3). Third, the variant proportions among 294 sequenced samples were used to estimate the variant-specific infection rates. However, as 295 these samples may not be representative of the NYC population, estimates may reflect biases in 296 the populations for which SARS-CoV-2 testing and sequencing were conducted. Lastly, per 297 recommendation of the Council of State and Territorial Epidemiologists (CSTE), COVID-19-298 associated deaths were classified using a revised definition based solely on cause of death listed 299 on the death certificate, for weeks from April 23, 2023 onwards. This revised definition could 300 lead to missing COVID-19-associated deaths and thus underestimation of IFR afterwards. 301 Nonetheless, a similar decline in IFR was estimated in the stratified analysis excluding weeks 302 after the revision (Table S1), indicating a true continued decline in IFR after the Omicron BA.1 303 wave.

304

- 305 In summary, using comprehensive epidemiological data and model inference, we have
- 306 described potential transmission dynamics of SARS-CoV-2 during its first 3.5 years of circulation
- 307 in NYC, a large, urban center. Study findings highlight immune evasion, transmissibility
- 308 increases, and higher infection risk during winter as key transmission drivers during the study
- 309 period; these may be observed in other populations and could inform future planning to help
- 310 mitigate the public health burden of SARS-CoV-2.
- 311

312 METHODS

313 Data sources and processing.

- 314 For the model-inference system, we utilized multiple sources of epidemiologic data, including
- 315 confirmed and probable COVID-19 cases, ED visits, deaths, vaccination, and variant proportions.
- 316 As done and described previously (11-13), we aggregated all COVID-19 confirmed and probable
- 317 cases (48, 49), COVID-19-associated ED visits (13, 50), and COVID-19-associated deaths (49)
- 318 reported to the NYC Health Department by age group (<1, 1-4, 5-14, 15-24, 25-44, 45-64, 65-74,
- and 75+ year-olds), neighborhood of residence (42 United Hospital Fund neighborhoods in NYC
- 320 (51)), and week of occurrence (13). For mortality, we note a change in COVID-19-associated
- death definitions. From March 1, 2020 April 2, 2023, COVID-19-associated deaths included 1)
- 322 deaths occurring in persons with laboratory-confirmed SARS-CoV-2 infection (i.e., confirmed
- 323 COVID-19-associated death) at any point (March 1, 2020 July 23, 2020), within 60 days (July
- 324 24, 2020 August 2, 2021), or within 30 days (August 3, 2021 April 2, 2023) of diagnosis; and
- 2) deaths with COVID-19, SARS-CoV-2 or a similar term listed on the death certificate as an
- immediate, underlying, or contributing cause of death but without laboratory-confirmation of
- 327 COVID-19 (i.e., probable COVID-19-associated death) (52). From April 3, 2023 through the week
- of August 27, 2023 (i.e., end of this study), COVID-19-associated deaths included any death
- 329 where the death certificate included COVID-19 or a common variation of COVID-19, SARS-CoV-
- 330 2, coronavirus, etc. (53). For vaccinations, we included all available vaccine doses to date (i.e.,
- 331 1st to 5th dose), and aggregated data for each vaccine dose to the same age/neighborhood
- 332 strata, by date of vaccination (54).
- 333

To model the impact of NPIs, as done previously (11-13), we used mobility data from SafeGraph

- 335 (47) to adjust SARS-CoV-2 transmission rate. Note, however, the model-inference system also
- included a parameter to capture the overall impacts of NPIs not limited to mobility reduction
- 337 (e.g., additional interventions such as masking; see below). The SafeGraph data were
- 338 aggregated to the neighborhood level by week without age stratification, and available from
- the week of March 1, 2020 to the week of December 19, 2022. For the week of December 26,
- 340 2022 to the week of August 27, 2023 (i.e., end of our study period), a comparison of historical
- 341 SafeGraph data (i.e., weeks during March 2020 December 2022, using the maximum mobility

- 342 recorded for the corresponding week of year to account for seasonal changes) showed a close
- 343 agreement with real-time subway ridership data (Fig S3). Thus, we used historical SafeGraph
- 344 data for those weeks.
- 345
- 346 To compute the variant-specific estimates, we used reported weekly percentage of individual
- 347 variants among sequenced samples (55, 56). Variant proportion data started from the week of
- 348 December 27, 2020, and likely did not fully capture the share of lota, a major variant that
- 349 emerged around Fall 2020. Therefore, we combined the ancestral and lota variants when
- 350 computing the total number of cases or infections attributable to these variants.
- 351
- 352 For model validation, we used SARS-CoV-2 wastewater surveillance data, available from August
- 353 31, 2020 onward. Specifically, SARS-CoV-2 RNA concentrations were measured at each of the
- 354 city's 14 wastewater treatment plants, often twice per week, using quantitative reverse
- 355 transcription polymerase chain reaction (RT-qPCR) assays during August 31, 2020 April 11,
- 356 2023 and reverse transcription digital PCR (RT-dPCR) assays from November 1, 2022 through
- the week of August 27, 2023 (i.e., end of this study). For weeks after April 11, 2023 when the
- 358 samples were measured using RT-dPCR alone, we converted the RT-dPCR measurements to RT-
- 359 qPCR equivalents, by multiplying a simple conversion ratio (i.e., the mean of all RT-qPCR
- 360 measurements dividing the mean of all RT-dPCR measurements during November 1, 2022 –
- 361 April 11, 2023 when both assays were conducted). To compute the citywide weekly per-capita
- 362 SARS-CoV-2 wastewater concentrations, we first averaged the per-capita SARS-CoV-2
- 363 concentrations (i.e., normalized by sewershed flow rate and population size) for each week and
- 364 sewershed, and then further aggregated the sewershed-level measurements to the city level
- 365 (i.e., weighted mean per the population size).
- 366

367 This activity was classified as public health surveillance and exempt from ethical review and

- 368 informed consent by the Institutional Review Boards of both Columbia University and NYC
- 369 Health Department.
- 370

371 Model inference to estimate key epidemiological variables and parameters

- We used a model-inference system to estimate epidemiological variables and parameters
- 373 based on case, ED visit, and mortality data, accounting for NPIs, vaccinations, under-detection
- of infection, and seasonal changes. Built on an approach described in Yang et al. (13), here the
- 375 model-inference system additionally tracks the number of vaccinated individuals and accounts
- 376 for all vaccine doses as done in ref (57). Briefly, the model-inference system uses a
- 377 metapopulation network SEIRSV (Susceptible-Exposed-Infectious-(re)Susceptible-Vaccination)
- 378 model (Eq. 1) to simulate the transmission of SARS-CoV-2 by age group and neighborhood:
- 379

380

381 where S_i, E_i, I_i, R_i, V_i, and N_i are the number of susceptible, exposed (but not yet infectious), 382 infectious, recovered and immune (i.e., protected against infection), vaccinated and immune 383 individuals, and the total population (58), respectively, from a given age group (i.e., <1, 1-4, 5-384 14, 15-24, 25-44, 45-64, 65-74, or 75+ years) in neighborhood-*i* (*i* = 1,...42, for the 42 385 neighborhoods in the city). β_{citv} is the average citywide transmission rate; b_s is the estimated 386 seasonal trend (12). The term b_i represents the neighborhood-level transmission rate relative to 387 the city average. The term m_{ij} represents the changes in contact rate in each neighborhood (for 388 *i=j*) or spatial transmission from neighborhood-*j* to *i* (for $i \neq j$) and was computed based on the 389 mobility data (12). Here, we did not explicitly model the impact of individual NPI such as 390 masking, due to the lack of data and the minor impact of masking at the population level 391 (estimated 5-20% reduction (11, 42, 59)). Rather, to account for the overall impact of NPIs 392 including masking, we scaled the mobility data by a multiplicative factor to capture the overall 393 NPI effectiveness when computing m_{ii} (12). Z, D, and L are the latency period, infectious period, 394 and immunity period, respectively. Note that as all state variables and parameters are time 395 varying and for each age group separately, Eq. 1 omits time (t) and age in the subscripts. 396

397 To account for vaccination, $v_{i,k}$ is the number of neighborhood-*i* residents who were

immunized after the *k*-th dose (*k* = 1, 2, ..., 5 here for up to 5 doses of vaccines to date) at the

time step (t), and was computed using vaccination data adjusting for vaccine effectiveness (VE)

400 against infection (60-64). Thus, the term $\sum_{k=1}^{k=K} v_{i,k}$ represents the total number of

401 neighborhood-*i* residents immunized by any dose of vaccine at the time step. The term

402 $\sum_{\tau=0}^{\tau=T} \rho_{\tau} V_{i,t-\tau}$ accounts for the waning of vaccine protection against infection, where $V_{i,t-\tau}$ is the

403 number of neighborhood-*i* residents who got vaccinated τ days ago and lost protection on day-

404 t, and ρ_{τ} is the VE waning probability computed based on VE duration data (63). Note, here we

405 focused on modeling the impact of vaccination on population susceptibility, and that the

406 posterior estimates of population susceptibility were made along with other factors (e.g.,

407 infection) using several data streams and model inference as described below.

408

- 409 Using the model-simulated number of infections occurring each day, we further computed the 410 number of cases, ED visits, and deaths each week to match with the observations, as described 411 in (*12*, *13*). Using cases as an example, we multiplied the model-simulated number of new
- 411 In (12, 13). Using cases as an example, we multiplied the model-simulated number of new
- 412 infections per day by the infection-detection rate (i.e., case ascertainment rate, or the fraction
- 413 of infections reported as cases), and further distributed these estimates in time per a
- 414 distribution of time-from-infection-to-case-detection (Table S3); we then aggregated the daily
- 415 lagged, simulated estimates to weekly totals for model inference.
- 416
- 417 Each week, the system uses the ensemble adjustment Kalman filter (EAKF) (65) to compute the
- 418 posterior estimates of model state variables and parameters based on the model (prior)
- 419 estimates and observed case, ED visit, and mortality data per Bayes' rule (12, 13). In particular,
- 420 model posterior estimates include 1) the underlying infection rate including those not reported
- 421 as cases, for each week (Fig 2A and C); 2) the number of susceptible individuals (i.e., *S_i*), which
- 422 provides estimates of population susceptibility over time (Fig 2B); 3) the citywide transmission
- 423 rate (β_{citv}) and infectious period (see estimates in Fig S2 B and C), which we multiplicatively
- 424 combined to compute the time-varying virus transmissibility (R_{TX} , as measure of variant-specific
- 425 infectiousness as described in (17, 22); Fig 2C); and 4) other key parameters such as the
- 426 infection-detection rate (Fig 3C), IFR (Fig 4), and the real-time production number (R_t ; see
- 427 estimates in Fig S2A).
- 428

429 We ran the model-inference system for the pre-Omicron and Omicron periods, separately. For 430 the pre-Omicron period, we initiated the system at the week of March 1, 2020 (i.e., the week

- 431 the first cases were detected in NYC), and ran it continuously through the week of December 5,
- 432 2021 (i.e., the week before the Omicron BA.1 variant was detected in >50% of sequenced
- 433 cases). For the Omicron period, we reinitiated the system at the week of November 21, 2021
- 434 and ran it continuously through the end of the study period; given the initial overlap with the
- 435 Delta variant in November/December 2021, we computed the number of cases, ED visits, and
- 436 deaths due to Omicron based on the variant proportion data and used those variant-specific
- 437 estimates for inference. To account for model uncertainty, we ran the model-inference system
- 438 10 times, each with 500 ensemble members randomly drawn from the initial prior ranges
- 439 (Table S3), and combined the posteriors from all runs, as done in (12).
- 440

441 Model validation using SARS-CoV-2 wastewater surveillance data

- 442 To validate model-inference estimates, we compared the infection prevalence estimates (i.e.,
- the estimated number of infectious individuals, including those not detected as cases, in the
- 444 population each week) to independent SARS-CoV-2 wastewater concentration data (i.e., the
- 445 collective SARS-CoV-2 viral shedding of the population, regardless of clinical testing practices).

- 446 While both quantities represent the presence of SARS-CoV-2 in the population, the
- 447 measurements are on different scales and viral shedding per infection could vary by the
- 448 infecting variant. Thus, for comparison, we separated the data into three periods: i) August 31,
- 449 2020 (i.e., the first day of wastewater surveillance) June 26, 2021, predominantly the
- 450 ancestral and lota variants; ii) June 27, 2021 (i.e., the first week the share of Delta exceeding
- 451 50% among the sequenced samples) November 20, 2021, predominantly the Delta variant;
- 452 and iii) November 21, 2021 (i.e., the first week Omicron BA.1 was detected) August 29, 2023
- 453 (i.e., the last wastewater sample during the study period), predominantly the Omicron
- 454 subvariants. We scaled the wastewater measurements by multiplying the ratio of mean
- 455 infection prevalence estimates and mean wastewater concentrations across all weeks of each
- 456 period, and overlay the two time series for visual inspection (see Fig 1B).
- 457

458 Estimating variant-specific infection rates

459 The weekly infection rate estimates from the model-inference system are based on surveillance

- 460 data combining all reported variants and thus represent infections by any variant circulating
- 461 during the week. To estimate the variant-specific infection rates for each week, we multiplied
- the overall infection rate estimate by the proportion among the sequenced samples for each
- 463 variant during that week. To compute the total variant-specific infection rate, we then summed
- the weekly estimates across all weeks that a given variant was detected. For each variant, to
- identify the main circulation period (i.e., calendar weeks when 95% of all infections occurred),
- 466 we recorded the first week that the cumulative infection rate surpassed 2.5% (i.e., the start)
- 467 and 97.5% (i.e., the end) of the total.
- 468

469 Qualitative illustration of immunity from vaccinations and infections by different variants.

- 470 The model-inference system accounted for immunity conferred by prior infection and
- 471 vaccination and waning (Eq. 1) to compute the posterior estimates of population susceptibility,
- 472 using epidemiological data and the EAKF inference algorithm as described above. However,
- 473 because the two immune components overlap (e.g., a recoveree could subsequently get
- 474 vaccinated and have mixed immunity for both) and the EAKF may not perfectly preserve mass
- 475 balance, it is difficult to separately quantify their contributions. Thus, to qualitatively examine
- 476 the population immunity landscape, we used the rolling sum of prior infection as a proxy of
- 477 infection-induced immunity and that of vaccinations as a proxy of vaccine-induced immunity
- 478 (shown in Fig 2B). Specifically, the rolling sum of prior infection was computed by adding all
- 479 estimated infections during the preceding 0.5*T*_{rs} days (i.e., the estimated half time of immunity
- 480 period; see Fig S2D). The rolling sum of vaccinations was computed by adding vaccinations of
- 481 the primary series, 3^{rd} , and 4^{th} , 5^{th} dose during the preceding $0.5T_{vax}$ days (T_{vax} is the estimated
- 482 vaccine-induced immunity period) and further multiplying the estimated variant-specific VE
- 483 (Table S3).

484

484						
485	Ackn	owledgments: This study was in part supported by the National Institute of Allergy and				
486	Infec	tious Diseases (AI145883 and AI175747), the Centers for Disease Control and Prevention				
487	(CDC) and the Council of State and Territorial Epidemiologists (CSTE; contract no.:				
488	NU38	8OT00297), and the National Science Foundation (DMS-2027369). The authors thank				
489	Laure	en Firestein for overseeing the data use agreement and facilitating data sharing for this				
490	proje	ect; Ramona Lall for providing syndromic surveillance emergency department data; Iris				
491	Chen	g for providing immunization data; Jubayer Ahmed, Nelson De La Cruz, Brandon Nguyen,				
492	and (Greta Ohanian for managing and providing wastewater data; Elizabeth Luoma and Rebecca				
493	Rohre	er for their management and provision of variant data; the NYC Health Department COVID data				
494	team	for overarching data management and provision of data for this project; and Shama				
495		a, Sharon Greene, Scott Harper, Elizabeth Luoma, Aaron Olson, Enoma Omoregie, Mamta				
496	-	kh, Celia Quinn, Ulrike Siemetzki-Kapoor, Faten Taki, and Gretchen Van Wye for their input				
497		nis manuscript.				
498						
499	Auth	or contributions: WY designed the study, developed the model-inference system,				
500		prmed the analysis, and wrote the first draft; HP and EL provided the COVID-19 case and				
501	-	rgency department visit data; WL provided the COVID-19-associated mortality data; EAW				
502		ided the SARS-CoV-2 wastewater surveillance data. HY compiled the mobility data. All				
503	authors contributed to the final draft.					
504						
505	Conf	lict of interest:				
506		authors declare that they have no conflict of interest.				
507						
508	Refe	rences:				
509	1.	E. Harris, WHO Declares End of COVID-19 Global Health Emergency. JAMA-J Am Med				
510		Assoc 329 , (2023).				
511	2.	H. E. Davis, L. McCorkell, J. M. Vogel, E. J. Topol, Long COVID: major findings,				
512		mechanisms and recommendations. Nat Rev Microbiol 21 , 133-146 (2023).				
513	3.	K. Koelle, M. A. Martin, R. Antia, B. Lopman, N. E. Dean, The changing epidemiology of				
514	4	SARS-CoV-2. Science 375 , 1116-1121 (2022).				
515 516	4.	Global Initiative on Sharing All Influenza Data (GISAID), Tracking of hCoV-19 Variants. https://www.gisaid.org/hcov19-variants/				
517	5.	S. Riley, K. E. C. Ainslie, O. Eales, C. E. Walters, H. Wang, C. Atchison, C. Fronterre, P. J.				
518	5.	Diggle, D. Ashby, C. A. Donnelly, G. Cooke, W. Barclay, H. Ward, A. Darzi, P. Elliott,				
519		Resurgence of SARS-CoV-2: Detection by community viral surveillance. <i>Science</i> 372 , 990-				
520		995 (2021).				
521	6.	P. Elliott, M. Whitaker, D. Tang, O. Eales, N. Steyn, B. Bodinier, H. Wang, J. Elliott, C.				
522		Atchison, D. Ashby, W. Barclay, G. Taylor, A. Darzi, G. S. Cooke, H. Ward, C. A. Donnelly,				

523		S. Riley, M. Chadeau-Hyam, Design and Implementation of a National SARS-CoV-2
525 524		Monitoring Program in England: REACT-1 Study. <i>Am J Public Health</i> 113 , 545-554 (2023).
525	7.	J. Brainard, I. R. Lake, R. A. Morbey, N. R. Jones, A. J. Elliot, P. R. Hunter, Comparison of
525 526	7.	surveillance systems for monitoring COVID-19 in England: a retrospective observational
527 528	0	study. Lancet Public Health 8, e850-e858 (2023).
528	8.	P. Sah, M. C. Fitzpatrick, C. F. Zimmer, E. Abdollahi, L. Juden-Kelly, S. M. Moghadas, B. H.
529		Singer, A. P. Galvani, Asymptomatic SARS-CoV-2 infection: A systematic review and
530		meta-analysis. Proc Natl Acad Sci U S A 118, (2021).
531	9.	Z. J. Feng, Q. Li, Y. P. Zhang, Z. Y. Wu, X. P. Dong, H. L. Ma, D. P. Yin, K. Lyu, D. Y. Wang, L.
532		Zhou, R. Q. Ren, C. Li, Y. L. Wang, D. Ni, J. Zhao, B. Li, R. Wang, Y. Niu, X. H. Wang, L. J.
533		Zhang, J. F. Sun, B. X. Liu, Z. Q. Deng, Z. T. Ma, Y. Yang, H. Liu, G. Shao, H. Li, Y. Liu, H. J.
534		Zhang, S. Q. Qu, W. Lou, D. Shan, Y. H. Hu, L. Hou, Z. P. Zhao, J. M. Liu, H. Y. Wang, Y. J.
535		Pang, Y. T. Han, Q. Y. Ma, Y. J. Ma, S. Chen, W. Li, R. T. Yang, Z. W. Li, Y. N. Guo, X. R. Liu,
536		B. Jiangtulu, Z. X. Yin, J. Xu, S. Wang, L. Xiao, T. Xu, L. M. Wang, X. Qi, G. Q. Shi, W. X. Tu,
537		X. M. Shi, X. M. Su, Z. J. Li, H. M. Luo, J. Q. Ma, J. M. McGoogan, The Epidemiological
538		Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China,
539		2020. China CDC Weekly 2 , 113-122 (2020).
540	10.	B. Rader, A. Gertz, A. D. Iuliano, M. Gilmer, L. Wronski, C. M. Astley, K. Sewalk, T. J.
541		Varrelman, J. Cohen, R. Parikh, Use of At-Home COVID-19 Tests—United States, August
542		23, 2021–March 12, 2022. Morbidity and Mortality Weekly Report 71 , 489 (2022).
543	11.	W. Yang, J. Shaff, J. Shaman, Effectiveness of non-pharmaceutical interventions to
544		contain COVID-19: a case study of the 2020 spring pandemic wave in New York City. J R
545		Soc Interface 18 , 20200822 (2021).
546	12.	W. Yang, S. Kandula, M. Huynh, S. K. Greene, G. Van Wye, W. Li, H. T. Chan, E.
547		McGibbon, A. Yeung, D. Olson, A. Fine, J. Shaman, Estimating the infection-fatality risk of
548		SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based
549		analysis. The Lancet Infectious Diseases 21 , 203-212 (2021).
550	13.	W. Yang, S. K. Greene, E. R. Peterson, W. Li, R. Mathes, L. Graf, R. Lall, S. Hughes, J.
550	15.	Wang, A. Fine, Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant.
552		Science Advances 8, eabm0300 (2022).
553	14.	
555 554	14.	The New York Times, New York City says it will end school mask and indoor proof-of-
		vaccination mandates. <u>https://www.nytimes.com/2022/02/27/nyregion/new-york-</u>
555	4 5	mask-mandate-schools.html
556	15.	P. Mlcochova, S. A. Kemp, M. S. Dhar, G. Papa, B. Meng, I. Ferreira, R. Datir, D. A. Collier,
557		A. Albecka, S. Singh, R. Pandey, J. Brown, J. Zhou, N. Goonawardane, S. Mishra, C.
558		Whittaker, T. Mellan, R. Marwal, M. Datta, S. Sengupta, K. Ponnusamy, V. S.
559		Radhakrishnan, A. Abdullahi, O. Charles, P. Chattopadhyay, P. Devi, D. Caputo, T.
560		Peacock, C. Wattal, N. Goel, A. Satwik, R. Vaishya, M. Agarwal, SCG. C. Indian, C.
561		Genotype to Phenotype Japan, CN. B. C Collaboration, A. Mavousian, J. H. Lee, J.
562		Bassi, C. Silacci-Fegni, C. Saliba, D. Pinto, T. Irie, I. Yoshida, W. L. Hamilton, K. Sato, S.
563		Bhatt, S. Flaxman, L. C. James, D. Corti, L. Piccoli, W. S. Barclay, P. Rakshit, A. Agrawal, R.
564		K. Gupta, SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature
565		599 , 114-119 (2021).

J. L. Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe, E.
Tessier, N. Groves, G. Dabrera, R. Myers, C. N. J. Campbell, G. Amirthalingam, M.
Edmunds, M. Zambon, K. E. Brown, S. Hopkins, M. Chand, M. Ramsay, Effectiveness of
Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* 385, 585-594 (2021).

- 571 17. W. Yang, J. L. Shaman, COVID-19 pandemic dynamics in South Africa and
 572 epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).
 573 *Elife* 11, e78933 (2022).
- 574 18. S. Cele, L. Jackson, D. S. Khoury, K. Khan, T. Moyo-Gwete, H. Tegally, J. E. San, D. Cromer, 575 C. Scheepers, D. G. Amoako, F. Karim, M. Bernstein, G. Lustig, D. Archary, M. Smith, Y. 576 Ganga, Z. Jule, K. Reedoy, S.-H. Hwa, J. Giandhari, J. M. Blackburn, B. I. Gosnell, S. S. 577 Abdool Karim, W. Hanekom, M.-A. Davies, M. Hsiao, D. Martin, K. Mlisana, C. K. Wibmer, 578 C. Williamson, D. York, R. Harrichandparsad, K. Herbst, P. Jeena, T. Khoza, H. Kløverpris, 579 A. Leslie, R. Madansein, N. Magula, N. Manickchund, M. Marakalala, M. Mazibuko, M. 580 Moshabela, N. Mthabela, K. Naidoo, Z. Ndhlovu, T. Ndung'u, N. Ngcobo, K. Nyamande, 581 V. Patel, T. Smit, A. Stevn, E. Wong, A. von Gottberg, J. N. Bhiman, R. J. Lessells, M.-Y. S. 582 Moosa, M. P. Davenport, T. de Oliveira, P. L. Moore, A. Sigal, Omicron extensively but
- incompletely escapes Pfizer BNT162b2 neutralization. *Nature* 602, 654-656 (2022).
 J. R. C. Pulliam, C. van Schalkwyk, N. Govender, A. von Gottberg, C. Cohen, M. J.
- 585 Groome, J. Dushoff, K. Mlisana, H. Moultrie, Increased risk of SARS-CoV-2 reinfection 586 associated with emergence of Omicron in South Africa. *Science* **376**, eabn4947 (2022).
- Q. Wang, Y. Guo, S. Iketani, M. S. Nair, Z. Li, H. Mohri, M. Wang, J. Yu, A. D. Bowen, J. Y.
 Chang, J. G. Shah, N. Nguyen, Z. Chen, K. Meyers, M. T. Yin, M. E. Sobieszczyk, Z. Sheng,
 Y. Huang, L. Liu, D. D. Ho, Antibody evasion by SARS-CoV-2 Omicron subvariants
 BA.2.12.1, BA.4 and BA.5. *Nature* 608, 603-608 (2022).
- Y. Cao, A. Yisimayi, F. Jian, W. Song, T. Xiao, L. Wang, S. Du, J. Wang, Q. Li, X. Chen, Y. Yu,
 P. Wang, Z. Zhang, P. Liu, R. An, X. Hao, Y. Wang, J. Wang, R. Feng, H. Sun, L. Zhao, W.
 Zhang, D. Zhao, J. Zheng, L. Yu, C. Li, N. Zhang, R. Wang, X. Niu, S. Yang, X. Song, Y. Chai,
 Y. Hu, Y. Shi, L. Zheng, Z. Li, Q. Gu, F. Shao, W. Huang, R. Jin, Z. Shen, Y. Wang, X. Wang,
 J. Xiao, X. S. Xie, BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron
 infection. *Nature* 608, 593-602 (2022).
- 597 22. W. Yang, J. Shaman, Development of a model-inference system for estimating
 598 epidemiological characteristics of SARS-CoV-2 variants of concern. *Nature*599 *Communications* 12, 5573 (2021).
- R. Anderson, C. Donnelly, D. Hollingsworth, M. Keeling, C. Vegvari, R. Baggaley, R.
 Maddren, Reproduction number (R) and growth rate (r) of the COVID-19 epidemic in the
 UK: methods of estimation, data sources, causes of heterogeneity, and use as a guide in
 policy formulation. *The Royal Society* 2020, (2020).
- E. Volz, S. Mishra, M. Chand, J. C. Barrett, R. Johnson, L. Geidelberg, W. R. Hinsley, D. J.
 Laydon, G. Dabrera, A. O'Toole, R. Amato, M. Ragonnet-Cronin, I. Harrison, B. Jackson, C.
 V. Ariani, O. Boyd, N. J. Loman, J. T. McCrone, S. Goncalves, D. Jorgensen, R. Myers, V.
 Hill, D. K. Jackson, K. Gaythorpe, N. Groves, J. Sillitoe, D. P. Kwiatkowski, C.-G. U.
 consortium, S. Flaxman, O. Ratmann, S. Bhatt, S. Hopkins, A. Gandy, A. Rambaut, N. M.

609 Ferguson, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature 610 593, 266-269 (2021). 611 25. D. H. Morris, K. C. Yinda, A. Gamble, F. W. Rossine, Q. Huang, T. Bushmaker, R. J. Fischer, 612 M. J. Matson, N. Van Doremalen, P. J. Vikesland, L. C. Marr, V. J. Munster, J. O. Lloyd-613 Smith, Mechanistic theory predicts the effects of temperature and humidity on 614 inactivation of SARS-CoV-2 and other enveloped viruses. *Elife* 10, (2021). 615 26. L. C. Marr, J. W. Tang, J. Van Mullekom, S. S. Lakdawala, Mechanistic insights into the 616 effect of humidity on airborne influenza virus survival, transmission and incidence. J R 617 Soc Interface 16, (2019). 618 W. Yang, L. C. Marr, Mechanisms by which ambient humidity may affect viruses in 27. 619 aerosols. Appl Environ Microbiol 78, 6781-6788 (2012). 620 28. E. Huynh, A. Olinger, D. Woolley, R. K. Kohli, J. M. Choczynski, J. F. Davies, K. Lin, L. C. 621 Marr, R. D. Davis, Evidence for a semisolid phase state of aerosols and droplets relevant 622 to the airborne and surface survival of pathogens. Proc Natl Acad Sci U S A 119, (2022). 623 29. L. Morawska, J. W. Tang, W. Bahnfleth, P. M. Bluyssen, A. Boerstra, G. Buonanno, J. Cao, 624 S. Dancer, A. Floto, F. Franchimon, C. Haworth, J. Hogeling, C. Isaxon, J. L. Jimenez, J. 625 Kurnitski, Y. Li, M. Loomans, G. Marks, L. C. Marr, L. Mazzarella, A. K. Melikov, S. Miller, 626 D. K. Milton, W. Nazaroff, P. V. Nielsen, C. Noakes, J. Peccia, X. Querol, C. Sekhar, O. 627 Seppänen, S.-i. Tanabe, R. Tellier, K. W. Tham, P. Wargocki, A. Wierzbicka, M. Yao, How 628 can airborne transmission of COVID-19 indoors be minimised? Environment 629 International 142, 105832 (2020). 630 30. T. W. Russell, N. Golding, J. Hellewell, S. Abbott, L. Wright, C. A. B. Pearson, K. van 631 Zandvoort, C. I. Jarvis, H. Gibbs, Y. Liu, R. M. Eggo, W. J. Edmunds, A. J. Kucharski, C. C.-632 w. group, Reconstructing the early global dynamics of under-ascertained COVID-19 633 cases and infections. BMC Med 18, 332 (2020). 634 A. T. Levin, W. P. Hanage, N. Owusu-Boaitey, K. B. Cochran, S. P. Walsh, G. Meyerowitz-31. 635 Katz, Assessing the age specificity of infection fatality rates for COVID-19: systematic 636 review, meta-analysis, and public policy implications. Eur J Epidemiol 35, 1123-1138 637 (2020). 638 32. M. O'Driscoll, G. R. Dos Santos, L. Wang, D. A. T. Cummings, A. S. Azman, J. Paireau, A. 639 Fontanet, S. Cauchemez, H. Salje, Age-specific mortality and immunity patterns of SARS-640 CoV-2. Nature, (2020). 641 33. W. S. Hoogenboom, A. Pham, H. Anand, R. Fleysher, A. Buczek, S. Soby, P. Mirhaji, J. Yee, 642 T. Q. Duong, Clinical characteristics of the first and second COVID-19 waves in the Bronx, 643 New York: A retrospective cohort study. Lancet Reg Health Am 3, 100041 (2021). 644 34. N. G. Davies, C. I. Jarvis, C. C.-W. Group, W. J. Edmunds, N. P. Jewell, K. Diaz-Ordaz, R. H. 645 Keogh, Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. 646 Nature 593, 270-274 (2021). 647 N. Wolter, W. Jassat, S. Walaza, R. Welch, H. Moultrie, M. Groome, D. G. Amoako, J. 35. 648 Everatt, J. N. Bhiman, C. Scheepers, N. Tebeila, N. Chiwandire, M. du Plessis, N. 649 Govender, A. Ismail, A. Glass, K. Mlisana, W. Stevens, F. K. Treurnicht, Z. Makatini, N.-y. 650 Hsiao, R. Parboosing, J. Wadula, H. Hussey, M.-A. Davies, A. Boulle, A. von Gottberg, C. 651 Cohen, Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in 652 South Africa: a data linkage study. The Lancet 399, 437-446 (2022).

653	36.	National Academies of Sciences, Engineering, and Medicine, Long-Term Health Effects of
654	50.	COVID-19: Disability and Function Following SARS-CoV-2 Infection. P. A. Volberding, B. X.
655		Chu, C. M. Spicer, Eds., (The National Academies Press, Washington, DC, 2024), pp. 264.
656	37.	L. Ungar, Pandemic gets tougher to track as COVID testing plunges.
657	57.	https://apnews.com/article/covid-us-testing-decline-
658		14bf5b0901260b063e4fa444633f4d31
659	38.	M. Kekatos, COVID call centers and testing sites close in further sign US is moving past
660	50.	the pandemic. <u>https://abcnews.go.com/Health/covid-call-centers-testing-sites-close-</u>
661		sign-us/story?id=97580639
662	39.	R. Stein, As the pandemic ebbs, an influential COVID tracker shuts down.
663	59.	https://www.npr.org/sections/health-shots/2023/02/10/1155790201/as-the-pandemic-
664	40	ebbs-an-influential-covid-tracker-shuts-down
665	40.	B. J. Silk, H. M. Scobie, W. M. Duck, T. Palmer, F. B. Ahmad, A. M. Binder, J. A. Cisewski,
666		S. Kroop, K. Soetebier, M. Park, A. Kite-Powell, A. Cool, E. Connelly, S. Dietz, A. E. Kirby,
667		K. Hartnett, J. Johnston, D. Khan, S. Stokley, C. R. Paden, M. Sheppard, P. Sutton, H.
668		Razzaghi, R. N. Anderson, N. Thornburg, S. Meyer, C. Womack, A. P. Weakland, M.
669		McMorrow, L. R. Broeker, A. Winn, A. J. Hall, B. Jackson, B. E. Mahon, M. D. Ritchey,
670		COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration-
671		United States, May 11, 2023. <i>Mmwr-Morbid Mortal W</i> 72, 523-528 (2023).
672	41.	The Council of State and Territorial Epidemiologists, Association of Public Health
673		Laboratories, Interim CSTE and APHL Strategic Framework for SARS-CoV-2 Infection and
674		COVID-19 Surveillance: Priorities and Approaches for State, Territorial, Local, and Tribal
675		Public Health Agencies. <u>https://preparedness.cste.org/wp-</u>
676	_	content/uploads/2022/10/Interim-CSTE-APHL-COVID-Surveillance-Framework.pdf
677	42.	W. Yang, J. Shaff, J. Shaman, Effectiveness of non-pharmaceutical interventions to
678		contain COVID-19: a case study of the 2020 spring pandemic wave in New York City. J R
679		Soc Interface 18 , 20200822 (2021).
680	43.	A. Lasry, D. Kidder, M. Hast, J. Poovey, G. Sunshine, K. Winglee, N. Zviedrite, F. Ahmed,
681		K. A. Ethier, CDC Public Health Law Program, New York City Department of Health and
682		Mental Hygiene, Louisiana Department of Health, Public Health Seattle and King County,
683		San Francisco COVID-Response Team, Alameda County Public Health Department, San
684		Mateo County Health Department, Marin County Division of Public Health, Timing of
685		Community Mitigation and Changes in Reported COVID-19 and Community Mobility -
686		Four U.S. Metropolitan Areas, February 26-April 1, 2020. MMWR. Morbidity and
687		mortality weekly report 69 , 451-457 (2020).
688	44.	M. U. G. Kraemer, C. H. Yang, B. Gutierrez, C. H. Wu, B. Klein, D. M. Pigott, CD. W. G.
689		Open, L. du Plessis, N. R. Faria, R. Li, W. P. Hanage, J. S. Brownstein, M. Layan, A.
690		Vespignani, H. Tian, C. Dye, O. G. Pybus, S. V. Scarpino, The effect of human mobility and
691		control measures on the COVID-19 epidemic in China. Science 368, 493-497 (2020).
692	45.	R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial undocumented
693		infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science
694		368 , 489-493 (2020).
695	46.	P. M. DeJonge, Wastewater surveillance data as a complement to emergency
696		department visit data for tracking incidence of influenza A and respiratory syncytial

697		virus—Wisconsin, August 2022–March 2023. MMWR. Morbidity and Mortality Weekly
698		Report 72 , (2023).
	47	
699 700	47.	SafeGraph, Weekly Patterns: Foot Traffic Data To Understand The COVID-19 Pandemic.
700	10	https://www.safegraph.com/weekly-foot-traffic-patterns
701	48.	Centers for Disease Control and Prevention, National Notifiable Diseases Surveillance
702		System (NNDSS) - Coronavirus Disease 2019 (COVID-19).
703		https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/
704	49.	New York City Department of Health and Mental Hygiene, Defining confirmed and
705		probable cases and deaths. <u>https://www1.nyc.gov/site/doh/covid/covid-19-data.page</u>
706	50.	R. Lall, J. Abdelnabi, S. Ngai, H. B. Parton, K. Saunders, J. Sell, A. Wahnich, D. Weiss, R. W.
707		Mathes, Advancing the Use of Emergency Department Syndromic Surveillance Data,
708		New York City, 2012-2016. <i>Public Health Rep</i> 132 , 23s-30s (2017).
709	51.	NewYork City Department of Health and Mental Hygiene, NYC UHF 42 Neighborhoods.
710		http://a816-dohbesp.nyc.gov/IndicatorPublic/EPHTPDF/uhf42.pdf
711	52.	New York City Department of Health and Mental Hygiene (DOHMH) COVID-19 Response
712		Team, Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak — New
713		York City, March 11–May 2, 2020. MMWR. Morbidity and mortality weekly report 69,
714		603-605 (2020).
715	53.	New York City Department of Health and Mental Hygiene, NYC Coronavirus Disease
716		2019 (COVID-19) Data. 1/10/2024. https://github.com/nychealth/coronavirus-data
717	54.	New York City Department of Health and Mental Hygiene, NYC Coronavirus 2019
718	51.	(COVID-19) Vaccine Data. <u>https://github.com/nychealth/covid-vaccine-data</u>
719	55.	C. N. Thompson, S. Hughes, S. Ngai, J. Baumgartner, J. C. Wang, E. McGibbon, K.
720	55.	Devinney, E. Luoma, D. Bertolino, C. Hwang, K. Kepler, C. Del Castillo, M. Hopkins, H.
721		Lee, A. K. DeVito, J. L. Rakeman, PhD, A. D. Fine, Rapid Emergence and Epidemiologic
722		Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-
723		April 5, 2021. <i>MMWR Morb Mortal Wkly Rep</i> 70 , 712-716 (2021).
724	56.	New york City Department of Health and Mental Hygiene, Variants.
724	50.	https://github.com/nychealth/coronavirus-data/tree/master/variants
725	57	
	57.	W. Yang, J. Shaman, Development of Accurate Long-lead COVID-19 Forecast. <i>PLoS</i>
727	50	Comput Biol 19 , e1011278 (2023).
728	58.	New York City Department of Health and Mental Hygiene, NYC DOHMH population
729		estimates, modified from US Census Bureau interpolated intercensal population
730		estimates, 2000-2018. Updated August 2019.
731	59.	J. X. Benjamin J Cowling, Escandón, Re: Effectiveness of public health measures in
732		reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality:
733		systematic review and meta-analysis. BMJ, (2021.
734		https://www.bmj.com/content/375/bmj-2021-068302/rr-14).
735	60.	F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G.
736		Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K.
737		Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L. Hammitt, O. Tureci, H. Nell, A.
738		Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Sahin, K. U. Jansen, W. C.
739		Gruber, C. C. T. Group, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N
740		Engl J Med 383 , 2603-2615 (2020).

741 742	61.	L. R. Baden, H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A. Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz,
743		C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich,
744		J. Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H. Bennett, R. Pajon, C. Knightly,
745		B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks, C. S. Group, Efficacy and
746		Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>N Engl J Med</i> 384 , 403-416 (2021).
747	62.	E. J. Haas, F. J. Angulo, J. M. McLaughlin, E. Anis, S. R. Singer, F. Khan, N. Brooks, M.
748		Smaja, G. Mircus, K. Pan, J. Southern, D. L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis,
749		Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and
750		COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination
751		campaign in Israel: an observational study using national surveillance data. The Lancet
752		397 , 1819-1829 (2021).
753	63.	UK Heath Security Agency, COVID-19 vaccine surveillance report (Week 17, 28 April
754		2022).
755		https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachm
756		ent_data/file/1072064/Vaccine-surveillance-report-week-17.pdf
757	64.	F. C. M. Kirsebom, N. Andrews, J. Stowe, S. Toffa, R. Sachdeva, E. Gallagher, N. Groves,
758		AM. O'Connell, M. Chand, M. Ramsay, J. L. Bernal, COVID-19 vaccine effectiveness
759		against the omicron (BA.2) variant in England. The Lancet Infectious Diseases.
760	65.	J. L. Anderson, An ensemble adjustment Kalman filter for data assimilation. Mon.
761		Weather Rev. 129 , 2884-2903 (2001).
762		

Figures

Fig 1. Model fit and validation. (A) Model fit to weekly number of COVID-19 cases, emergency department (ED) visits, and deaths, during the week starting 03/01/20 (mm/dd/yy) to the week starting 08/27/23 (see x-axis). Blue lines show the median estimates and blue areas show 50% (darker) and 95% (lighter) credible intervals (CrIs); dots show the corresponding observations. (B) Model validation using wastewater surveillance data, for the 2nd wave (left panel), Delta wave (middle panel), the Omicron period (right panel). Lines and shaded areas show the estimated infection prevalence (i.e., the number of all infectious individuals including those not detected as cases; median, 50% and 95% CrIs; left y-axis). Dots show measured SARS-CoV-2 concentrations in wastewater (right y-axis, in million copies per day per population) for the corresponding weeks (black dots show measurements using RT-qPCR and red dots show measurements using RT-dPCR but converted to RT-qPCR equivalents; note that the wastewater concentrations are scaled for each wave/period to facilitate comparison with model estimates; see Methods for details).




Fig 2. Estimated infection rates (A), population immunity dynamics (B), and virus transmissibility (C). In (A), colored bars show estimated median weekly infection rates, for each variant (see legends). In (B), we overlay estimated population susceptibility [left y-axis; blue line = median, blue areas = 50% (darker) and 95% (lighter) CrIs], and proxies of cumulative infection (colored stacked bars from top to bottom, right y-axis; same legends as in A for different variants) and vaccine-induced immunity against infection (open bars; see Methods). In (C), we show estimated virus transmissibility [left y-axis; blue line = median, blue areas = 50% (darker) and 95% (lighter) CrIs] and infection rates [boxplot and right y-axis; middle bar = median, edges = 50% CrIs, and whiskers = 95% CrIs] for the corresponding weeks.






Fig 3. Infection annual pattern and detection rates. (A) shows estimated infection rates (light blue bars, full height; i.e., not stacked) and reported case rates (darker blue portion) by month; error bars show estimated 95% CrIs. To examine the infection annual pattern, (B) shows the monthly infection rates scaled to the annual maximum (here, a year starts in September, the start of fall/cold months in the Northern hemisphere, and ends in the next August, the end of winter/cold months in Southern hemisphere). March – August 2020 is not shown due to the incompleteness. (C) shows estimated infection-detection rate [blue line = median, blue areas = 50% (darker) and 95% (lighter) CrIs], for each week. Note the vertical dashed line indicates the week starting 11/21/21 when Omicron BA.1 was first detected in NYC, and estimates to the right of the dashed line are for Omicron (sub)variants alone.








Fig 4. Estimated infection-fatality risk (IFR) over time, by age group (A-E) and overall (F). Blue lines and shaded areas show the median estimates and 50% (darker blue) and 95% (lighter blue) CrIs, for each week (see date of week start in mm/dd/yy in the x-axis). For clarity, insets show estimates during the most recent months.




Table 1. Estimated cumulative infection rate, by variant. For ease of comparison, we convert the number of detected cases and estimated infections to percentage relative to the size of NYC's population (columns labeled "% population"), i.e., this percentage does not refer to unique individuals detected as cases or estimated to experience infections.

Variant	Main circulation period	Cases detec	cted	Estimated infections	
		n (×1000)ª	% population ^b	n (×1000)ª	% population ^b
All		3,207	38.2%	17,383 (14,154, 21,549)	207% (168.5%, 256.6%)
Pre-Omicron		1,162	13.8%	4,509 (3,673, 5,423)	53.7% (43.7%, 64.6%)
Omicron		2,046	24.4%	12,875 (10,481, 16,126)	153.3% (124.8%, 192%)
BA.1	12/12/2021 - 02/05/2022	1,024	12%	3,468 (2,188, 5,624)	41.3% (26.1%, 67%)
Ancestral/lota	03/08/2020 - 04/17/2021	834	9.9%	3,195 (1,653, 6,334)	38% (19.7%, 75.4%)
BA.5	06/05/2022 - 12/03/2022	289	3.4%	2,107 (1,148, 4,589)	25.1% (13.7%, 54.6%)
XBB.1.5	11/27/2022 - 08/12/2023	175	2.1%	1,783 (790, 5,018)	21.2% (9.4%, 59.7%)
BA.2.12.1	04/10/2022 - 07/16/2022	145	1.7%	881 (462, 1,948)	10.5% (5.5%, 23.2%)
Delta	06/27/2021 - 12/11/2021	225	2.7%	704 (327, 1,792)	8.4% (3.9%, 21.3%)
BA.2	02/13/2022 - 07/23/2022	128	1.5%	621 (332, 1,375)	7.4% (4%, 16.4%)
BQ.1	10/02/2022 - 01/07/2023	61	0.73%	591 (311, 1,338)	7% (3.7%, 15.9%)
BQ.1.1	10/09/2022 - 01/28/2023	58	0.7%	566 (295, 1,287)	6.7% (3.5%, 15.3%)
XBB	10/23/2022 - 09/02/2023	37	0.44%	439 (214, 1,181)	5.2% (2.5%, 14.1%)
FL.1	05/07/2023 - 09/02/2023	13	0.16%	243 (117, 709)	2.9% (1.4%, 8.4%)
Alpha	01/17/2021 - 06/12/2021	77	0.92%	240 (128, 471)	2.9% (1.5%, 5.6%)
BA.4.6	06/19/2022 - 11/19/2022	32	0.39%	238 (130, 523)	2.8% (1.5%, 6.2%)
XBB.1.16	04/23/2023 - 09/02/2023	13	0.16%	234 (100, 802)	2.8% (1.2%, 9.5%)
BA.4	05/22/2022 - 09/24/2022	32	0.39%	223 (121, 481)	2.7% (1.4%, 5.7%)
EG.5	05/21/2023 - 09/02/2023	11	0.14%	209 (99 <i>,</i> 617)	2.5% (1.2%, 7.3%)
BA.2.75	09/04/2022 - 08/19/2023	13	0.15%	124 (62, 310)	1.5% (0.7%, 3.7%)
XBB.1.9	03/05/2023 - 09/02/2023	5	0.056%	75 (30, 268)	0.9% (0.4%, 3.2%)
BF.7	08/07/2022 - 12/24/2022	8	0.1%	74 (38, 172)	0.9% (0.5%, 2%)
Epsilon	12/27/2020 - 04/17/2021	10	0.11%	25 (15, 45)	0.3% (0.2%, 0.5%)
Gamma	03/21/2021 - 07/17/2021	4	0.052%	16 (8, 38)	0.2% (0.1%, 0.5%)
Mu	04/11/2021 - 09/25/2021	3	0.035%	12 (6, 33)	0.1% (0.1%, 0.4%)

^aThe numbers are shown in thousands (i.e., ×1000). ^bThe percentages are relative to the city's population size of 8.39 million residents.

Table 2. Estimated virus transmissibility (R_{TX}) and overall infection-fatality risk (IFR) during each wave/period. Numbers show the median estimate (and 95% credible intervals). Note the calendar periods here were chosen based on the rough timing of pandemic waves (March – May 2020 for the 1st wave, October 2020 – May 2021 for the 2nd wave, July – November 2021 for the Delta wave, and December 2021 – August 2023 for Omicron subvariants; see Fig 1), matching with the weekly intervals (hence the listed start dates) and excluding weeks with mixed circulation of variants (hence the missing weeks) in order to obtain more variant-specific estimates.

Wave/variants	Calendar period	R _{TX}	IFR (%)
1st wave (ancestral)	03/01/20 - 05/30/20	2.4 (1.33-3.68)	1.429 (0.979-1.903)
2nd wave	10/04/20 - 05/29/21	2.86 (1.73-	0.397 (0.246-0.6)
(ancestral/lota/Alpha)		4.29)	
Delta	07/04/21 - 12/04/21	3.75 (2.12-	0.241 (0.094-0.602)
		5.75)	
Omicron BA.1	12/12/21 - 02/26/22	5.46 (3.73-	0.095 (0.047-0.166)
		7.35)	
After BA.1	03/06/22 - 09/02/23	6.38 (4.15-	0.056 (0.022-0.136)
		9.37)	

Supplemental Figures and Tables

Fig S1. Model fits by age group. Boxplots show model estimates of COVID-19 cases (A and B), ED visits (C and D), and deaths (E and F) per 100,000 population (middle bar = median, edges = 50% CrIs, and whiskers = 95% CrIs), for each age group (see subtitle) and week (see x-axis, mm/dd/yy). Red dots show the corresponding observations.




Fig S2. Estimates for key epidemiological variables: (A) the real-time effective reproduction number Rt, (B) citywide transmission rate (β_{city} in Eq. 1) (C) infectious period, and (D) immunity period (T_{rs} in Eq. 1). Blue lines and shaded areas show the median estimates and 50% (darker blue) and 95% (lighter blue) CrIs, for each week (see date of week start in mm/dd/yy in the x-axis). The vertical dashed line indicates the week starting 11/21/21 when Omicron BA.1 was first detected in NYC.




Fig S3. Trends in population mobility during the study period. Relative mobility for each week is computed by dividing the mobility for each week by that during the week starting March 1, 2020 (i.e., the pandemic onset in NYC). SafeGraph data were available from the week of March 1, 2020 to the week of December 19, 2022 (red solid line), and used in this study. For the week of December 26, 2022 to the week of August 27, 2023, we used trends constructed with historical SafeGraph data (i.e., weeks during March 2020 – December 2022, using the maximum mobility recorded for the corresponding week of year to account for seasonal changes; red dashed line). Real-time subway ridership data (blue line) are shown for comparison.




Table S1. Estimated infection-fatality risk (IFR, %), for individual age groups, during each wave/period. Numbers show the median estimate (and 95% credible intervals). The last two rows show stratified estimates for weeks post-BA.1, before and after the revision of COVID-19 death definition following the recommendation of the Council of State and Territorial Epidemiologists (CSTE).

Wave/variants	Calendar period	all ages	<25 years	25-44 years	45-64 years	65-74 years	75+ years
1st wave (ancestral)	03/01/20 -	1.4291	0.0099	0.1117	1.1992	4.6334	12.2835
	05/30/20	(0.9793-1.903)	(0.0046-	(0.0706-	(0.8047-	(2.7199-	(7.3515-
			0.0151)	0.1466)	1.5056)	6.9133)	16.9023)
2nd wave	10/04/20 -	0.3965	0.0047	0.0379	0.324	1.9044	5.5573 (3.238-
(ancestral/lota/Alpha)	05/29/21	(0.2461-	(0.0019-	(0.0174-	(0.2013-	(0.9849-	7.5487)
		0.6004)	0.0088)	0.0673)	0.5231)	3.1934)	
Delta	07/04/21 -	0.2406	0.004 (0.0019-	0.04 (0.0209-	0.3436	0.9821	2.4551
	12/04/21	(0.0936-	0.0061)	0.0598)	(0.1906-	(0.2883-	(0.9768-
		0.6016)			0.5516)	2.6949)	5.4612)
Omicron BA.1	12/12/21 -	0.0945	0.0017 (6e-04-	0.0106	0.0842	0.3921	1.5588
	02/26/22	(0.0474-	0.0029)	(0.0042-	(0.0441-	(0.2286-	(0.9388-
		0.1663)		0.0202)	0.147)	0.5353)	2.1269)
After BA.1 (all weeks)	03/06/22 -	0.0561	0.0018 (5e-04-	0.0098	0.0352	0.1457	0.4927
	09/02/23	(0.0219-	0.0032)	(0.0016-	(0.0071-	(0.0471-	(0.2496-
		0.1355)		0.0208)	0.1249)	0.3591)	1.0303)
After BA.1 (before	03/06/22 -	0.0621	0.0018 (5e-04-	0.0095	0.0357	0.1587	0.5885
revision of COVID-19	04/22/23	(0.0274-	0.0032)	(0.0018-	(0.0083-	(0.0588-0.358)	(0.3186-
death definition) ^a		0.1349)		0.0202)	0.1207)		1.0814)
After BA.1 (after	04/23/23 -	0.0373	0.0017 (3e-04-	0.0109	0.0337	0.1055	0.1951
revision of COVID-19	09/02/23	(0.0048-	0.0034)	(0.0012-	(0.0036-	(0.0107-	(0.0355-
death definition) ^b		0.1375)		0.0227)	0.138)	0.3625)	0.8716)

^aBefore April 22, 2023, COVID-19-associated deaths included deaths occurring in persons with laboratory-confirmed SARS-CoV-2 infection, and deaths with COVID-19, SARS-CoV-2, or a similar term listed on the death certificate as an immediate, underlying, or contributing cause of death but did not have laboratory-confirmation of COVID-19.

^bFrom April 23, 2023 onward, COVID-19-associated deaths included any death where the death certificate includes COVID-19 or a common variation of COVID-19, SARS-CoV-2, coronavirus, etc.

Table S2. Correlation between infection-detection rate and population mobility, during the early weeks of the 1st pandemic wave and the Omicron BA.1 wave. Numbers show the mean (and 95% confidence intervals [CI]) of Pearson's correlation coefficients during the first 4, 6, and 8 weeks (column "First N weeks") of the two pandemic waves. These results show estimated infection-detection rates were negatively correlated with observed population mobility during the early weeks of both pandemic waves; that is, initial increases in community mitigation via social distancing (as indicated by decreases in population mobility) coincided with increases in infection-detection rate. Note the Omicron BA.1 wave spread rapidly, peaked ~1 month following the initial introduction, and subsided within ~2 months; thus, the inverse association was the strongest during the first 4 weeks (vs. the first 8 weeks for the 1st pandemic wave).

Wave	First N	Calendar period	Correlation (95% CI)	P-value	
	weeks				
1 st wave	4	03/01/2020 - 04/04/2020	-0.8 (-1, 0.69)	0.2	
	6	03/01/2020 - 04/18/2020	-0.82 (-0.98, -0.02)	0.046	
	8	03/01/2020 - 05/02/2020	-0.81 (-0.96, -0.24)	0.015	
Omicron	4	11/21/2021 - 12/25/2021	-0.96 (-1 <i>,</i> -0.05)	0.035	
BA.1 wave	6	11/21/2021 - 01/08/2022	-0.29 (-0.89, 0.68)	0.58	
	8	11/21/2021 - 01/22/2022	-0.28 (-0.82, 0.53)	0.5	

Period	Parameter	Symbol	Age group	Range	Note
	Vaccine efficacy (VE)		All	Before Delta: VE1=85%, VE2 = 95%; Delta: VE1 = 35.6%, VE2 = 88%, VE3 = 90%; Omicron: VE1 = 35%, VE2 = 70%, VE3 = 70%, VE4 = 70%, VE5 (bivalent) = 90%	Based on VE against symptomatic disease
	VE waning	ρ	All	rho(t) = 1/(1+exp(-k * (t - tm.imm/2); for wildtype: k = 0.026; tm.imm = 322; for Delta: k = 0.025; tm.imm = 280; for Omicron: k = 0.024; tm.imm = 256	Parameter in the logistic function fitted based on data from UKHSA (ref 63)
Pre- Omicron	Citywide transmission rate (per day)	β_{city}	<1 year	U [0.25, 0.5]	Uniform distribution, based on an overall transmission rate of 0.5–1 and adjusting for contact rate for the age group (same below)
Pre- Omicron	Citywide transmission rate (per day)	β_{city}	1-4 years	U [0.26, 0.52]	-
Pre- Omicron	Citywide transmission rate (per day)	β_{city}	5-14 years	U [0.33, 0.67]	-
Pre- Omicron	Citywide transmission rate (per day)	β_{city}	15-24 years	U [0.38, 0.77]	-
Pre- Omicron	Citywide transmission rate (per day)	β_{city}	25-44 years	U [0.69, 1.4]	-
Pre- Omicron	Citywide transmission rate (per day)	β_{city}	45-64 years	U [0.5, 1]	-

Pre- Omicron	Citywide transmission rate (per day)	β_{city}	65-74 years	U [0.25, 0.5]	-	
Pre- Omicron	Citywide transmission rate (per day)	β_{city}	75+ years	U [0.25, 0.5]	-	
Pre- Omicron	Latency period (days)	Z	All	U [2, 5]	-	
Pre- Omicron	Infectious period (days)	D	All	U [2, 5]	-	
Pre- Omicron	Immunity period (days)	L	<1 year	U [180, 550]	-	
Pre- Omicron	Immunity period (days)	L	1-4 years	U [910, 1300]	-	
Pre- Omicron	Immunity period (days)	L	5-14 years	U [910, 1300]	-	
Pre- Omicron	Immunity period (days)	L	15-24 years	U [910, 1300]	-	
Pre- Omicron	Immunity period (days)	L	25-44 years	U [910, 1300]	-	
Pre- Omicron	Immunity period (days)	L	45-64 years	U [910, 1300]	-	
Pre- Omicron	Immunity period (days)	L	65-74 years	U [910, 1300]	-	
Pre- Omicron	Immunity period (days)	L	75+ years	U [910, 1300]	-	
Pre- Omicron	Time-to-detection, mean (days)	Td, mean	All	U [3, 8]	-	
Pre- Omicron	Time-to-detection, SD (days)	Td,sd	All	U [1, 3]	-	
Pre- Omicron	Infection-detection rate	IDR	<1 years	U [0.001, 0.05]	-	

Pre-	Infection-detection	IDR	1-4 years	U [1e-04, 0.05]	-
Omicron	rate				
Pre-	Infection-detection	IDR	5-14 years	U [1e-04, 0.05]	-
Omicron	rate				
Pre-	Infection-detection	IDR	15-24	U [1e-04, 0.05]	-
Omicron	rate		years		
Pre-	Infection-detection	IDR	25-44	U [0.001, 0.05]	-
Omicron	rate		years		
Pre-	Infection-detection	IDR	45-64	U [0.001, 0.05]	-
Omicron	rate		years		
Pre-	Infection-detection	IDR	, 65-74	U [0.001, 0.05]	-
Omicron	rate		years	. , .	
Pre-	Infection-detection	IDR	75+ years	U [0.001, 0.05]	-
Omicron	rate		,		
Pre-	Infection-fatality	IFR	<1 years	U [5e-05, 0.00015]	_
Omicron	risk		vi years	0 [50 05, 0.00015]	
Pre-	Infection-fatality	IFR	1-4 years	U [5e-05, 0.00015]	-
Omicron	risk		I ycurs	0 [50 05, 0.00015]	
Pre-	Infection-fatality	IFR	5-14 years	U [5e-05, 0.00015]	<u>_</u>
Omicron	risk		J IF years	0 [50 05, 0.00015]	
Pre-	Infection-fatality	IFR	15-24	U [5e-05, 0.00015]	-
Omicron	risk			0 [58-05, 0.00015]	-
Pre-	Infection-fatality	IFR	years 25-44	U [5e-04, 0.0015]	
	•	IFR		0 [58-04, 0.0015]	-
Omicron	risk	150	years		
Pre-	Infection-fatality	IFR	45-64	U [0.005, 0.015]	-
Omicron	risk		years		
Pre-	Infection-fatality	IFR	65-74	U [0.01, 0.1]	-
Omicron	risk		years		
Pre-	Infection-fatality	IFR	75+ years	U [0.02, 0.2]	-
Omicron	risk				
Pre-	Infection-to-ED	EDR	<1 years	U [0.005, 0.1]	-
Omicron	ratio				

Pre- Omicron	Infection-to-ED ratio	EDR	1-4 years	U [0.005, 0.1]	-	
Pre- Omicron	Infection-to-ED ratio	EDR	5-14 years	U [1e-04, 0.02]	-	
Pre- Omicron	Infection-to-ED ratio	EDR	15-24 years	U [0.001, 0.03]	-	
Pre- Omicron	Infection-to-ED ratio	EDR	25-44 years	U [0.001, 0.03]	-	
Pre- Omicron	Infection-to-ED ratio	EDR	45-64 years	U [0.001, 0.06]	-	
Pre- Omicron	Infection-to-ED ratio	EDR	65-74 years	U [0.01, 0.2]	-	
Pre- Omicron	Infection-to-ED ratio	EDR	75+ years	U [0.01, 0.3]	-	
Omicron	Citywide transmission rate (per day)	β_{city}	<1 years	U [0.61, 0.8]	-	
Omicron	Citywide transmission rate (per day)	β_{city}	1-4 years	U [0.66, 0.85]	-	
Omicron	Citywide transmission rate (per day)	β_{city}	5-14 years	U [0.91, 1.2]	-	
Omicron	Citywide transmission rate (per day)	β_{city}	15-24 years	U [1, 1.3]	-	
Omicron	Citywide transmission rate (per day)	β_{city}	25-44 years	U [1.6, 2.1]	-	
Omicron	Citywide transmission rate (per day)	β_{city}	45-64 years	U [1.2, 1.6]	-	

Omicron	Citywide transmission rate (per day)	β_{city}	65-74 years	U [0.6, 0.76]	-
Omicron	Citywide transmission rate (per day)	β_{city}	75+ years	U [0.58, 0.75]	-
Omicron	Latency period (days)	Z	<1 years	U [2.2, 3.8]	-
Omicron	Latency period (days)	Z	1-4 years	U [2.1, 3.6]	-
Omicron	Latency period (days)	Z	5-14 years	U [2, 3.5]	-
Omicron	Latency period (days)	Z	15-24 years	U [2.1, 3.6]	-
Omicron	Latency period (days)	Z	25-44 years	U [2.3, 3.8]	-
Omicron	Latency period (days)	Z	45-64 years	U [2.2, 3.6]	-
Omicron	Latency period (days)	Z	65-74 years	U [2.2, 3.7]	-
Omicron	Latency period (days)	Z	75+ years	U [2.2, 3.7]	-
Omicron	Infectious period (days)	D	<1 years	U [2.2, 2.9]	-
Omicron	Infectious period (days)	D	1-4 years	U [2.7, 3.5]	-
Omicron	Infectious period (days)	D	5-14 years	U [2.9, 3.7]	-
Omicron	Infectious period (days)	D	15-24 years	U [3.5, 4.5]	-
Omicron	Infectious period (days)	D	25-44 years	U [3.2, 4.1]	-

Omicron	Infectious period (days)	D	45-64 years	U [3.3, 4.2]	_	
Omicron	Infectious period (days)	D	65-74 years	U [2.5, 3.2]	-	
Omicron	Infectious period (days)	D	75+ years	U [2.7, 3.5]	-	
Omicron	Immunity period (days)	L	<1 years	U [360, 470]	-	
Omicron	Immunity period (days)	L	1-4 years	U [360, 1000]	-	
Omicron	Immunity period (days)	L	5-14 years	U [360, 1100]	-	
Omicron	Immunity period (days)	L	15-24 years	U [360, 1000]	-	
Omicron	Immunity period (days)	L	25-44 years	U [360, 850]	-	
Omicron	Immunity period (days)	L	45-64 years	U [360, 1100]	-	
Omicron	Immunity period (days)	L	65-74 years	U [360, 990]	-	
Omicron	Immunity period (days)	L	75+ years	U [360, 960]	-	
Omicron	Time-to-detection, mean (days)	Td, mean	<1 years	U [3.7, 5.2]	-	
Omicron	Time-to-detection, mean (days)	Td, mean	1-4 years	U [3.7, 5]	-	
Omicron	Time-to-detection, mean (days)	Td, mean	5-14 years	U [3.8, 4.9]	-	
Omicron	Time-to-detection, mean (days)	Td, mean	15-24 years	U [3.3, 4.3]	-	
Omicron	Time-to-detection, mean (days)	Td, mean	25-44 years	U [4, 4.9]	-	

Omicron	Time-to-detection, mean (days)	Td, mean	45-64 years	U [3.9, 4.8]	_
Omicron	Time-to-detection, mean (days)	Td, mean	65-74 years	U [4.2, 5.2]	-
Omicron	Time-to-detection, mean (days)	Td, mean	75+ years	U [4, 4.8]	-
Omicron	Time-to-detection, SD (days)	Td,sd	<1 years	U [1.5, 2.1]	-
Omicron	Time-to-detection, SD (days)	Td,sd	1-4 years	U [1.6, 2.2]	_
Omicron	Time-to-detection, SD (days)	Td,sd	5-14 years	U [1.7, 2.3]	-
Omicron	Time-to-detection, SD (days)	Td,sd	15-24 years	U [1.6, 2.2]	_
Omicron	Time-to-detection, SD (days)	Td,sd	25-44 years	U [1.9, 2.5]	-
Omicron	Time-to-detection, SD (days)	Td,sd	45-64 years	U [2, 2.5]	_
Omicron	Time-to-detection, SD (days)	Td,sd	65-74 years	U [1.7, 2.2]	-
Omicron	Time-to-detection, SD (days)	Td,sd	75+ years	U [1.7, 2.1]	-
Omicron	Infection-detection rate	IDR	All	U [0.01, 0.05]	-
Omicron	Infection-fatality risk	IFR	<1 years	U [6.1e-06, 2.8e-05]	-
Omicron	Infection-fatality risk	IFR	1-4 years	U [6.2e-06, 2.8e-05]	-
Omicron	Infection-fatality risk	IFR	5-14 years	U [6.2e-06, 2.8e-05]	_
Omicron	Infection-fatality risk	IFR	15-24 years	U [6e-06, 2.7e-05]	_

Omicron	Infection-fatality risk	IFR	25-44 years	U [4.3e-05, 0.00024]	-
Omicron	Infection-fatality risk	IFR	45-64 years	U [0.00039, 0.0021]	-
Omicron	Infection-fatality risk	IFR	65-74 years	U [0.0015, 0.005]	-
Omicron	Infection-fatality risk	IFR	75+ years	U [0.0037, 0.014]	-
Omicron	Infection-to-ED ratio	EDR	<1 years	U [0.0035, 0.029]	-
Omicron	Infection-to-ED ratio	EDR	1-4 years	U [0.0019, 0.013]	-
Omicron	Infection-to-ED ratio	EDR	5-14 years	U [0.00061, 0.0047]	-
Omicron	Infection-to-ED ratio	EDR	15-24 years	U [0.001, 0.0083]	-
Omicron	Infection-to-ED ratio	EDR	25-44 years	U [0.00097, 0.0069]	-
Omicron	Infection-to-ED ratio	EDR	45-64 years	U [0.0028, 0.019]	-
Omicron	Infection-to-ED ratio	EDR	65-74 years	U [0.0024, 0.017]	-
Omicron	Infection-to-ED ratio	EDR	75+ years	U [0.006, 0.041]	-